Physician profile
Jonathan Ramos
NPI 1487045399
$1,712.41
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $192 · 2021: $328 · 2022: $97.26 · 2023: $194 · 2024: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $229.36 | 2019-2021 | |
| Allergan, INC. | $159.03 | 2019-2020 | |
| Amgen INC. | $150.09 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $145.80 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $129.45 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.28 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Lilly USA, LLC | $118.52 | 2019-2023 | Mounjaro |
| Abbvie INC. | $94.52 | 2019-2022 | |
| Astellas Pharma US INC | $73.06 | 2019 | |
| Genentech USA, INC. | $64.90 | 2019-2022 | |
| Abbott Laboratories | $56.97 | 2019 | |
| Pfizer INC. | $43.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $37.61 | 2020-2023 | Gardasil 9 |
| Ethicon US, LLC | $26.95 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.47 | 2019 | |
| Abiomed | $22.81 | 2024 | Impella |
| Shire North American Group INC | $18.62 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.34 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $13.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.26 | 2021 | |
| Amarin Pharma, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.